prikaz prve stranice dokumenta Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study
Access restricted to students and staff of home institution
Scientific paper - Preliminary note / Short communication
Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study
Journal of Neuroimmunology, 359 (2021); 577696. https://doi.org/10.1016/j.jneuroim.2021.577696
Habek, Mario; Jakob Brecl, Gregor; Bašić Kes, Vanja; Rogić, Dunja; Barun, Barbara; Gabelić, Tereza; Emeršič, Andreja; Horvat Ledinek, Alenka; Grbić, Nevena; Lapić, Ivana; Šegulja, Dragana; Đurić, Koraljka; Adamec, Ivan; Krbot Skorić, Magdalena

Cite this document

Habek, M., Jakob Brecl, G., Bašić Kes, V., Rogić, D., Barun, B., Gabelić, T. ... Krbot Skorić, M. (2021). Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study. Journal of Neuroimmunology, 359.. doi: 10.1016/j.jneuroim.2021.577696

Habek, Mario, et al. "Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study." Journal of Neuroimmunology, vol. 359, 2021. https://doi.org/10.1016/j.jneuroim.2021.577696

Habek, Mario, Gregor Jakob Brecl, Vanja Bašić Kes, Dunja Rogić, Barbara Barun, Tereza Gabelić, Andreja Emeršič, et al. "Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study." Journal of Neuroimmunology 359 (2021). https://doi.org/10.1016/j.jneuroim.2021.577696

Habek, M., et al. (2021) 'Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study', Journal of Neuroimmunology, 359. doi: 10.1016/j.jneuroim.2021.577696

Habek M, Jakob Brecl G, Bašić Kes V, Rogić D, Barun B, Gabelić T, and sur.. Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study. Journal of Neuroimmunology [Internet]. 2021 October [cited 2024 October 26];359. doi: 10.1016/j.jneuroim.2021.577696

M. Habek, et al., "Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study", Journal of Neuroimmunology, vol. 359, October 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:220:960921. [Accessed: 26 October 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study
AuthorMario Habek
AuthorGregor Jakob Brecl
AuthorVanja Bašić Kes
AuthorDunja Rogić
AuthorBarbara Barun
AuthorTereza Gabelić
AuthorAndreja Emeršič
AuthorAlenka Horvat Ledinek
AuthorNevena Grbić
AuthorIvana Lapić
AuthorDragana Šegulja
AuthorKoraljka Đurić
AuthorIvan Adamec
AuthorMagdalena Krbot Skorić
Author's institution(Sestre milosrdnice University Hospital Center)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract (english)
Aim: To determine the influence of high-efficacy disease modifying therapy (DMT) on the development of IgG SARS-CoV-2 antibody response in COVID-19 convalescent people with multiple sclerosis (pwMS). Methods: Seventy-four pwMS taking high-efficacy DMTs (specifically natalizumab, fingolimod, alemtuzumab, ocrelizumab, cladribine and ublituximab) and diagnosed with COVID-19 and 44 healthy persons (HC) were enrolled. SARS-CoV2 antibodies were tested with Elecsys® Anti-SARSCoV-2 S assay. Results: pwMS taking high-efficacy DMTs had a significantly higher chance of having negative titer of SARS-CoV2 antibodies compared to healthy controls (33 negative pwMS [44.6%] compared to one negative HC [2.3%], p < 0.001). pwMS taking B-cell depleting therapy (ocrelizumab and ublituximab) had a significantly higher chance of having negative titer of SARS-CoV2 antibodies compared to pwMS on all other DMTs (29 negative pwMS on B-cell therapy [64.4%] compared to four negative pwMS on all other DMTs [13.8%], p < 0.001). Out of other DMTs, two (33.3%) pwMS taking fingolimod and two (16.7%) pwMS taking cladribine failed to develop IgG SARS-COV-2 antibodies. B-cell depleting therapy independently predicted negative titer of IgG SARS-CoV-2 antibody (Exp[B] =0.014, 95%CI 0.002–0.110, p < 0.001). Conclusions: A significant proportion of convalescent COVID-19 pwMS on high-efficacy DMTs will not develop IgG SARS-CoV-2 antibodies. B-cell depleting therapies independently predict negative and low titer of IgG SARS-CoV-2 antibody.
Keywords (english)
Languageenglish
Publication typeScientific paper - Preliminary note / Short communication
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Neuroimmunology
Numberingvol. 359, 577696
p-ISSN0165-5728
DOIhttps://doi.org/10.1016/j.jneuroim.2021.577696
URN:NBNurn:nbn:hr:220:960921
Publication2021-10
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S016557282100223X
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2024-06-24 11:06:36